Floatz logo

Ensartinib

Recurrent Peripheral Primitive Neuroectodermal Tumor

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Recurrent Peripheral Primitive Neuroectodermal Tumor cohort.

Asset / SponsorPhaseRating
Palbociclib
National Cancer Institute (NCI)
Phase 2B
PI3K/MTOR INHIBITOR LY3023414
National Cancer Institute (NCI)
Phase 2B
Tazemetostat
National Cancer Institute (NCI)
Phase 2B
VEMURAFENIB
National Cancer Institute (NCI)
Phase 2CCC
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2CCC

View all 18 →

Same molecule, other indications

Ensartinib is also rated in:

MPRDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
Neoadjuvant TherapyDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →